Dec 15, 2016 · In two phase 3 trials of identical design involving patients with atopic dermatitis, dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety...

DUPIXENT® (dupilumab) is a subcutaneous injectable prescription medicine for uncontrolled moderate-to-severe eczema (atopic dermatitis) in adults & children aged 6 months & older. Serious side effects can occur.

Jul 10, 2014 · The blockade by dupilumab of these key drivers of type 2 helper T-cell (Th2)–mediated inflammation could help in the treatment of related diseases, including atopic dermatitis.

DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Feb 28, 2024 · Dupilumab is an injectable prescription medication administered subcutaneously to treat severe and refractory forms of atopic dermatitis. The US Food and Drug Administration (FDA) approved the medication in April 2017 to treat moderate-to-severe, resistant, atopic dermatitis unresponsive to conventional therapy, including topical corticosteroids.

Jan 2, 2016 · Interpretation: Dupilumab improved clinical responses in adults with moderate-to-severe atopic dermatitis in a dose-dependent manner, without significant safety concerns. Our findings show that IL-4 and IL-13 are key drivers of atopic dermatitis.

Mar 12, 2025 · Dupilumab treatment for up to 3 years is safe and effective for children aged 6 months to 11 years with atopic dermatitis (), according to study results presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting held in Orlando, Florida from March 7 to 11.Researchers performed an open-label extension (OLE) study (ClinicalTrials.gov Identifier: NCT02612454) that included ...

Keywords: atopic dermatitis, dupilumab, biologics, interleukin-4, interleukin-13, systemic treatment. Introduction. Atopic dermatitis (AD) is one of the most common chronic and relapsing inflammatory skin diseases worldwide.

Feb 19, 2025 · Among patients with atopic dermatitis (AD), dupilumab was associated with a favorable cardiometabolic safety profile within the first year of treatment when compared with methotrexate and cyclosporine, according to the results of a study published in the Archives of Dermatological Research.. The population-based, retrospective cohort study evaluated the real-world risk of 8 cardiovascular and ...

Dupilumab is a new treatment option for patients with moderate-to-severe atopic dermatitis. It blocks IL-4/IL13-signaling and thereby inhibits receptor signaling downstream the JAK-STAT-pathway.

Findings In this open-label extension study of 2677 adults with moderate to severe atopic dermatitis, dupilumab was well tolerated with no new safety incidents and showed sustained efficacy (including improvements in atopic dermatitis …

Question What is the clinical effectiveness of dupilumab for long-term use in patients with atopic dermatitis (AD), and what are reasons to discontinue dupilumab treatment?

Mar 12, 2025 · While Dupilumab was the first biologic approved for atopic dermatitis, showing excellent results in improving pruritus and sleep within two weeks, it may paradoxically affect sleep in some cases.

Background: Significant unmet need exists for long-term treatment of moderate to severe atopic dermatitis (AD). Objective: To assess the long-term safety and efficacy of dupilumab in patients with AD.

Mar 14, 2025 · Dupilumab-treated participants with recalcitrant head and neck symptoms who were switched to upadacitinib rapidly reached EASI 75 and steadily improved, among other findings. ... in achieving significant skin clearance across all anatomical regions in adults and adolescents with moderate-to-severe atopic dermatitis (AD) after 16 weeks of ...

Dupilumab improves general health-related quality-of-life in patients with moderate-to-severe atopic dermatitis: pooled results from two randomized, controlled phase 3 clinical trials. Dermatol Ther (Heidelb) 2017;7(2):243–248. doi: 10.1007/s13555-017-0181-6.

Silverberg JI, Simpson EL, Ardeleanu M, et al. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.

Aug 23, 2024 · Long-term use of dupilumab was well-tolerated and had sustained efficacy in adult patients with moderate to severe atopic dermatitis (AD), according to study results published in JAMA Dermatology.

Aug 1, 2024 · Importance: Moderate to severe atopic dermatitis (AD) is a chronic inflammatory skin disease that often requires continuous long-term systemic management. Long-term safety and efficacy data for treatment options are critically important.

Oct 10, 2019 · Dupilumab is a subcutaneously injected monoclonal antibody for people with moderate–severe atopic dermatitis who require systemic therapy. It is intended for long-term rather than episodic use and can be given with or without topical corticosteroids.